**:Sina**.
On December 15, 2023, the 4th China Biopharmaceutical Industry Chain Innovation and Transformation International Summit and the 4th China Biopharmaceutical Industry Chain Innovation Billboard Award Ceremony initiated by the China Biopharmaceutical Industry Chain Innovation and Transformation Consortium (hereinafter referred to as "CBIITA Consortium") kicked off in Hangzhou, and Kelun Pharmaceutical won the annual award for the most innovative enterprise with the most R&D strength.
Forge ahead with a reputation and forge ahead. In recent years, Kelun has efficiently integrated domestic and foreign resources, and achieved comprehensive integration with the international advanced level in terms of global R&D dynamic information, drug R&D technology platform and functional system construction. From 2017 to July 31, 2023, 152 generic drugs have been approved for production, 14 innovative drugs have been approved for clinical research, and 3 innovative drugs have been accepted by the NDA. The relevant person in charge of Kelun said that in the future, we will take honor as the driving force, carry forward the past and forge ahead into the future, seek well-being for human health, and make new contributions to promoting the development of national medicine.
The China Biopharmaceutical Industry Chain Innovation and Transformation Alliance was initiated by 10 well-known pharmaceutical academic communities at home and abroad, including the China Chemical Pharmaceutical Industry Association, the Chinese Pharmacological Society, the Chinese Society of Toxicology, the Chinese Drug Administration Research Association, the Global Society of Industrial Microbiology, and the China-Europe Life Science Alliance. International Technology Transfer", "Accelerating Innovation and Transformation", "Empowering Subversive Innovation", "Service Decision-making" and other functions, carry out service activities, and contribute to the innovation and transformation of China's biomedical industry chain.